Forcilin

Quick links to important sections

Forcilin

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Forcilin

Property Description
Active Ingredient Modafinil (INN)
Form Tablet (for oral use)
Pharmacological Class Wakefulness-Promoting Agent
General Purpose To combat excessive daytime sleepiness
Origin Synthetic compound

What Type of Medicine is Forcilin?

Forcilin is a prescription-only pharmaceutical preparation whose active component is the synthetic compound Modafinil (INN). It is classified as a wakefulness-promoting agent or psychoanaleptic, a distinction clinically recognized for its ability to enhance mental function and alertness. This categorization establishes its specific function in promoting vigilance and increasing alertness. Modafinil functions as an atypical CNS stimulant, differentiating its mechanism from traditional psychostimulants. This provides a targeted method for sustaining wakefulness in adult patients.

Composition and Form: The Synthetic Origin of Modafinil

The medication is a single active ingredient product containing only the substance Modafinil. Forcilin is formulated for oral administration in the pharmaceutical form of a tablet. Modafinil is derived entirely through synthetic chemical processes and is supplied as a racemic compound, meaning it is composed of both the R- and S-enantiomers. The R-enantiomer, known as Armodafinil, is the pharmacologically dominant component, a key feature that distinguishes Modafinil from its analogue preparations.

General Purpose and Benefit of a Psychoanaleptic

The general purpose of Forcilin is to counter persistent, unwarranted excessive sleepiness by sustaining wakefulness during the day. This is particularly relevant in scenarios where individuals experience continuous drowsiness that interferes with daytime activity. The drug's mechanism, which involves interaction with the dopamine transporter to inhibit dopamine reuptake, is recognized for its effectiveness in regulating arousal and the sleep-wake cycle. The primary therapeutic benefit of the agent is to improve the ability to maintain necessary alertness and daytime vigilance.

What side effects are possible with Forcilin?

Possible Side Effects and Safety Information

The safety profile of Forcilin (Modafinil) is officially classified by regulatory documents, which categorize potential adverse reactions by frequency and affected body system. The most frequently documented reactions are associated with the Nervous System and the Gastrointestinal Tract.


Frequency-Classified Adverse Reactions

Adverse reactions are formally classified based on the reported rate of occurrence, as outlined in official labeling:

Frequency Classification Examples (Organ Class Focus)
Very Common (ge 1/10) Headache, Insomnia (Nervous System)
Common (ge 1/100 to < 1/10) Nervousness, Dizziness, Nausea, Dry mouth, Tachycardia, Hypertension

These effects constitute the most frequently expected patterns associated with the drug's use. The official safety information further notes that symptoms like rash or other hypersensitivity reactions typically appear within the first one to five weeks of initiating treatment.


Serious Adverse Reactions and Safety Constraints

Regulatory authorities mandate specific warnings for rare but critical events. These include Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Drug Rash with Eosinophilia and Systemic Symptoms (DRESS). Other documented serious risks involve Psychiatric Events, including new-onset psychosis, mania, or severe depression, and reports of serious cardiac arrhythmias.

Official prescribing information includes specific limitations on use. It is contraindicated in individuals with known hypersensitivity to Modafinil or its analogue, Armodafinil. Caution is advised, and use is restricted, in patients with pre-existing left ventricular hypertrophy or severe hepatic impairment, as documented in government labeling. The drug’s metabolism requires careful consideration in populations with hepatic or renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help: Forcilin

This section outlines the officially documented overdose information for Forcilin as specified in government regulatory documents.

Documented Overdose Manifestations

Overdose presentations typically affect the central nervous, cardiovascular, and gastrointestinal systems. Symptoms documented in regulatory sources include:

  • Neurological: Seizures, tremors, dystonia, and dyskinesia.
  • Psychiatric: Psychosis, mania, hallucinations, agitation, and suicidal ideation.
  • Cardiovascular: Severe hypertension, tachycardia (rapid heart rate), chest pain, and cardiac arrhythmias (irregular heartbeat).

Required Emergency Actions

Immediate medical attention is required for the presence of severe manifestations such as seizures, severe hypertension, cardiac events, or symptoms suggesting a life-threatening complication.

Overdose Management

Overdose management is primarily supportive and symptomatic, focusing on stabilizing the patient's vital signs and treating the specific complications that arise. The official prescribing information indicates that no specific antidote is available for Forcilin overdose. Measures such as the administration of activated charcoal or continuous monitoring may be required.

Therapeutic Uses of Forcilin

Forcilin is commonly used to help with excessive daytime sleepiness (EDS) in adults, a symptom that creates noticeable functional strain and interferes with daily functioning. The application of this medication includes addressing core sleep-wake disorders. The medication may assist with promoting and supporting wakefulness, which helps with maintaining vigilance throughout the day.


The medication is applied in addressing sleepiness across three specific clinical conditions: narcolepsy, residual sleepiness associated with Obstructive Sleep Apnea (OSAHS), and the drowsiness related to Shift Work Sleep Disorder (SWSD). Symptomatic relief may assist with easing the overall symptom load of EDS.

In clinical scenarios, Forcilin is applied in addressing conditions where symptoms may intensify temporarily, such as when primary treatment requires additional symptomatic support. It assists with maintaining functional stability during scheduled work hours for shift workers and helps manage overwhelming drowsiness in primary sleep disorders.


Quick Fact: Therapeutic Goal for Excessive Daytime Sleepiness Forcilin helps manage chronic and persistent drowsiness that affects daily function, supporting the patient during episodes of heightened discomfort to improve day-to-day comfort.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Forcilin (Modafinil) eligibility is strictly defined by regulatory authorities and is restricted to the adult population (18 years and older).

Contraindicated Populations (Must Not Use)

The medicine is contraindicated and must not be used by:

  • Patients with a known hypersensitivity to modafinil or armodafinil.
  • Women who are pregnant or breastfeeding (lactation). Women of childbearing potential must use non-hormonal contraception during treatment and for two months after stopping.
  • Patients with uncontrolled moderate to severe hypertension or cardiac arrhythmias (per European labeling).

Age and Condition Restrictions

Population / Condition Official Regulatory Status
Pediatric Use (Under 18) Not approved/Not recommended. Safety and efficacy are not established in children.
Severe Hepatic Impairment Dose adjustment required. The dose must be reduced to one-half of the recommended amount.
Geriatric Patients (Over 65) Use of lower initial doses and close monitoring is recommended.
Pre-existing Heart Conditions Use not recommended in patients with a history of left ventricular hypertrophy or certain forms of mitral valve prolapse after prior CNS stimulant use.

Official documents also advise caution and monitoring for patients with a history of psychosis, depression, or mania.

What should I know about interactions with other medicines?

Forcilin Interactions with other medicines and products

This section describes the officially documented interaction profile of Forcilin with other medicinal products and substances, as established by authoritative government regulatory agencies. It outlines known or predicted interactions that require adjustments to drug selection or patient management.

Interacting Drug Categories and Agents

Interaction Domain Relevant Product Categories
Drug Metabolism Modulation Agents that significantly inhibit or induce CYP3A4 enzyme activity (e.g., strong CYP3A4 inhibitors/inducers)
Transport System Effects Medicines affecting P-glycoprotein ( P-gp) transport
Additive QT Prolongation Risk Other drugs known to prolong the QT interval

Official Interaction Statements

  • Strong CYP3A4 Inhibitors: Co-administration with strong CYP3A4 inhibitors is documented to increase the exposure of Forcilin, which may necessitate a reduction in the Forcilin dose to maintain safe and effective levels.
  • Strong CYP3A4 Inducers: Co-administration with strong CYP3A4 inducers is documented to decrease the exposure of Forcilin, which may require increasing the Forcilin dose to achieve the desired therapeutic effect.
  • P-gp Inhibitors: Concomitant use with agents that inhibit P-gp may increase the plasma concentration of Forcilin, and monitoring or dose adjustment may be required.
  • QT Prolonging Drugs: The concurrent use of Forcilin with other medicines that are known to prolong the QT interval requires careful assessment due to the potential for additive pharmacodynamic effects on cardiac rhythm.

These statements define the necessary clinical constraints for co-prescribing, focusing on the impact of other substances on Forcilin's metabolic clearance and transport, as well as the risk of pharmacodynamic overlap.

Mechanism of Action

Targeted Modulation of Central Arousal Pathways

Forcilin's mechanism involves the activation of the brain's two key wake-promoting systems: Orexin and Histamine. This is achieved by reducing GABAergic inhibitory input to the hypothalamic neurons that release these signaling molecules. The resulting functional disinhibition enhances the release of both Orexin and Histamine. This cascade results in a functional shift in the homeostatic balance of the sleep-wake cycle toward the wake state, which promotes a more stable state of central arousal.

Atypical Interaction with the Dopaminergic System

The drug also influences arousal through its interaction with the Dopamine Transporter (DAT). Forcilin acts as a weak, selective inhibitor of dopamine reuptake, increasing the concentration of dopamine in the synapse in regions that influence vigilance and attention. This binding is considered atypical, resulting in a distinct, slower kinetic profile compared to other substances that bind the DAT, influencing systems associated with alertness.

Multifaceted Action on the Sleep-Wake Cycle

The combined action across these distinct mechanistic domains—Orexin/Histamine disinhibition and atypical dopamine modulation—results in the sustained physiological ability to support the wake state and increased central signaling associated with alertness. The simultaneous engagement of these multiple, complementary pathways is the basis for the drug's effect profile, resulting in a persistent modulation of the central sleep-wake cycle's regulatory balance.

Dosage and Administration Information

Forcilin, containing Modafinil, is administered exclusively via the oral route using the tablet formulation (available in 100 mg and 200 mg strengths). The general administration principle requires the medication to be taken once daily, with precise timing depending on the treated indication.

The standard daily regimen for adults managing conditions like narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS) is 200 mg, typically taken in the morning. When used for Shift Work Sleep Disorder (SWSD), the dose is scheduled to be administered approximately one hour prior to the start of the work shift to synchronize its effect with necessary vigilance. This medication may be ingested with or without food.

The maximum recommended daily dosage is 400 mg. Standard clinical protocols include dose adjustments for specific physiological constraints: for patients with severe hepatic impairment, the prescribed dosage should be reduced by half, often equating to 100 mg daily. Lower doses should also be considered when prescribing to older adults. While the treatment addresses chronic conditions, the continued need for long-term use should be periodically re-evaluated by a healthcare professional.

Recent Clinical Evidence

Research evidence / Overview of studies for Forcilin

The research evidence for Forcilin (Modafinil) primarily comes from clinical trials and reviews that was studied for the management of excessive daytime sleepiness (EDS) linked to three specific, officially recognized conditions. These studies help show what has been observed so far in specific groups of adult patients.


Evidence for use in Narcolepsy

Clinical studies was studied in individuals with narcolepsy are mainly short-term, randomized controlled trials (RCTs). Researchers used established objective tests, such as the Maintenance of Wakefulness Test (MWT), to measure performance in monitoring wakefulness during the day. Studies reported patterns observed in the scores of scales used to track subjective sleepiness. Long-term effects are not fully established by controlled data, and the evidence base relies heavily on a limited number of short-term RCTs.

Evidence for Excessive Sleepiness Associated with OSAHS

The research foundation for Forcilin was studied in individuals experiencing excessive sleepiness linked to Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS). These were typically short-term, placebo-controlled RCTs involving adult patients whose underlying OSAHS was already receiving primary management (e.g., nCPAP). Controlled trials documented the outcomes on subjective sleepiness scores and performance on wakefulness tests. The evidence is limited regarding the use of Forcilin in patients whose primary OSAHS treatment was not the focus of the studies.

Evidence for Excessive Sleepiness Associated with Shift Work Sleep Disorder (SWSD)

For patients with sleepiness related to Shift Work Sleep Disorder (SWSD), research was conducted through intermediate-term (up to 12 weeks), placebo-controlled RCTs. These studies evaluated adult patients experiencing symptoms related to shift schedules. Research monitored outcomes related to daily functioning, primarily focusing on subjective sleepiness and objective performance metrics related to vigilance. Long-term effects are not fully established and remain uncertain for this population.

What is Still Uncertain About Forcilin Research

Data for certain groups remain insufficient, such as pediatric populations, older adults, or pregnant women. Long-term effects are not fully established by the controlled data, meaning the durability of observed changes over years remains an area where more research is needed. Findings were observed in some studies to show variability across results, and comparative evidence is lacking for certain therapeutic alternatives.

Key Studies & References

  1. Modafinil Mechanism of Action Study (Example of pharmacological basis used in background)
  2. NIH MedlinePlus Drug Information: Modafinil

Frequently Asked Questions (FAQ)

Common questions about Forcilin (FAQ)

Q: How quickly should I expect to feel a difference after starting Forcilin?

A: According to official regulatory documents, the time it takes to reach maximum concentration in the blood is generally observed to be between 2 to 4 hours after taking the dose, based on pharmacokinetic studies. If the medication is taken with food, this peak time may be slightly delayed.

Q: What makes Forcilin different from other medications used for the same condition?

A: Forcilin is classified as a wakefulness-promoting agent, or 'eugeroic.' Its effects involve the activation of the brain's natural wake-promoting systems, such as the orexin and histamine pathways. This multifaceted and atypical influence on the dopamine system differentiates its mechanism from traditional psychostimulants.

Q: Do many people experience upset stomach or nausea with Forcilin?

A: Official information from clinical trials lists nausea as a common side effect, meaning it was reported in up to 10% of patients. Other common symptoms affecting the digestive system include diarrhea and dry mouth.

Q: Is it normal to feel a little dizzy when first taking Forcilin?

A: Dizziness is documented in official safety information as a common adverse reaction. A common side effect is one that affects at least 1 out of every 100 people who take the medication.

Q: Can Forcilin cause changes in sleep patterns?

A: Yes, insomnia (difficulty sleeping) is the most frequently reported side effect in clinical trials. Regulatory documents classify insomnia as a very common reaction, meaning it can occur in 1 out of every 10 people.

Q: What are some of the less common but more serious side effects of Forcilin?

A: Serious adverse reactions noted in official warnings include severe skin rash, such as Stevens-Johnson Syndrome (SJS), and multi-organ hypersensitivity (DRESS). Other serious risks include new-onset psychiatric events like mania, psychosis, or severe depression, which require immediate medical attention.

Q: How long does Forcilin stay in your system after the last dose?

A: The drug has a mean elimination half-life of approximately 12 to 15 hours. Clearance from the body depends on several half-lives. You should consult a healthcare professional for specific concerns about clearance time.

Q: Are there any specific vitamins or supplements that interact with Forcilin?

A: Official interaction statements warn about substances that influence the liver's CYP3A4 enzyme system. While specific vitamins are not usually named, patients are generally advised to discuss all herbal products or supplements with a healthcare professional before starting treatment.

Q: Does drinking alcohol while taking Forcilin reduce its effectiveness?

A: Regulatory information advises avoiding alcohol while taking this medication. Combining Forcilin with alcohol may increase the risk of certain side effects, such as dizziness, although the specific interaction level is often not fully established.

Q: Are there special considerations for taking Forcilin while pregnant or breastfeeding?

A: The medication is not recommended for use during pregnancy or while breastfeeding. Furthermore, official documents require that women of childbearing potential must use effective non-hormonal contraception during treatment and for two months after the medicine is stopped.

Q: What is the process for discontinuing Forcilin?

A: Because this medication is a controlled substance and carries a risk of physical dependence, official guidance indicates that abrupt discontinuation should be avoided. Any change to the dosage schedule, including stopping the medication, is a clinical decision that must be made by a healthcare provider.

Q: What happens if I miss a dose of Forcilin?

A: General patient guidance suggests that a missed dose may be taken if remembered soon after and before the next planned sleep period. If a significant amount of time has passed, it is generally recommended to skip the missed dose. It is important to follow the instructions provided by the prescribing physician.

Q: If Forcilin is helping, how long until the treatment plan is re-evaluated?

A: Official prescribing information requires that the continued need for long-term use be periodically re-evaluated by a healthcare professional. This is based on the fact that the efficacy and safety of treatment lasting longer than 9 weeks are not fully established by controlled studies.

Q: Is it common for the initial side effects of Forcilin to wear off after a few days?

A: Regulatory documents do not provide a specific timeline for when common side effects like headache or dizziness typically resolve. However, the patient information notes that more serious reactions, such as rash, usually appear within the first 1 to 5 weeks of starting the medicine.

Q: What should I do if I suspect an allergic reaction to Forcilin?

A: If symptoms suggestive of a severe allergic reaction (such as rash, fever, or swelling of the face) occur, the medication must be discontinued. In this event, prompt emergency medical attention should be sought, as these can be life-threatening events.

Q: Is Forcilin similar to [Name of a common similar drug]?

A: The medication is classified as a Schedule IV controlled substance, which is a lower classification for potential abuse than many traditional Schedule II stimulant medications. Its pharmacological action is considered atypical compared to these traditional stimulants.

Q: Can certain foods or drinks affect how well Forcilin works?

A: While taking it with food does not change the total amount of drug absorbed, it can delay how quickly it starts working by about one hour. Specific food and beverage interactions, such as those involving grapefruit juice or caffeine, are matters to be discussed with a healthcare provider.

Q: Is Forcilin safe for people who have kidney issues?

A: Official prescribing information contains limited data to guide dosing and determine the full safety profile in patients with renal (kidney) impairment. Due to this lack of information, caution and close monitoring are typically recommended.

Q: Where can I find reliable studies about the long-term effects of Forcilin?

A: Official sources state that the long-term effectiveness of the drug beyond nine weeks has not been fully evaluated by controlled studies. Reliable, public information regarding the drug can typically be found through reputable government databases such as the U.S. National Library of Medicine (NIH).

Q: Does Forcilin require any regular blood tests while taking it?

A: Routine monitoring of liver enzymes is not specifically required by official labels for patients without pre-existing liver disease. However, if a patient develops signs of liver dysfunction, blood tests may be required to check liver function.

Q: Is Forcilin generally considered a short-term or long-term medication?

A: The drug is prescribed to manage chronic conditions associated with excessive sleepiness. However, the regulatory documents require that the need for its continued use be re-evaluated periodically because the safety and efficacy of long-term use (beyond 9 weeks) have not been fully studied.

Q: What is the proper way to dispose of unused Forcilin?

A: Because this is a controlled substance, official disposal instructions mandate that it be returned to a local drug take-back program or pharmacy collection point. If no program is available, guidance suggests mixing it with an undesirable substance (like coffee grounds) and sealing it before placing it in household trash.

Q: Does Forcilin interact with birth control pills?

A: Yes, official regulatory documents confirm that Forcilin can interfere with the effectiveness of hormonal contraceptives, including birth control pills. This is due to its effect on the liver enzymes that break down the hormones. Women are required to use a non-hormonal method of birth control during treatment and for two months afterward.

Q: Can Forcilin affect mood or cause emotional changes?

A: Official warnings note that the medication can be associated with the development of new or worsening psychiatric symptoms. These may include, but are not limited to, anxiety, agitation, depression, mania, psychosis, and suicidal thoughts.

Q: Are there different brand names or generics available for Forcilin?

A: Forcilin is the brand name for the active ingredient Modafinil. Generic versions of Modafinil are available, and the drug is also sold under other brand names.

Q: Does Forcilin affect my ability to drive or operate machinery?

A: Because this medication may affect alertness or coordination, patients are advised not to drive or perform complex tasks until they are fully aware of how the drug impacts them.

Q: Why do some people take Forcilin for conditions not listed in the main uses?

A: The official label only approves the drug for excessive sleepiness related to narcolepsy, Obstructive Sleep Apnea, and Shift Work Sleep Disorder. Its safety and effectiveness for any other medical condition have not been formally established by regulatory agencies.

Q: Is Forcilin considered a maintenance medication?

A: While it is used for chronic conditions, regulatory documents require that the need for the drug must be re-evaluated periodically. This is because the safety and efficacy of its continued use have not been fully established.

Q: Can Forcilin be taken at the same time as my other morning medications?

A: The drug is often taken once in the morning, but due to potential drug-drug interactions (especially concerning liver enzymes like CYP3A4), all concurrent medications must be reviewed by a healthcare provider or pharmacist to ensure appropriate management.

Q: How is Forcilin excreted from the body?

A: Official pharmacokinetic information indicates that the drug is extensively metabolized in the liver. The resulting inactive substances are then eliminated from the body primarily through the urine.

Q: What level of efficacy is generally reported for Forcilin in clinical settings?

A: Clinical trials reported patterns of observed improvement in objective tests (like the MWT) and subjective measures (like sleepiness scales) in patients with narcolepsy, OSAHS, and SWSD when compared to a placebo. The results suggested a general benefit for promoting wakefulness.

Q: What kind of monitoring is typically done when a patient is on Forcilin?

A: Official warnings require that patients be regularly monitored for possible increases in blood pressure and heart rate. Additionally, periodic clinical assessments are necessary to re-evaluate the ongoing need for long-term treatment.

How should Forcilin be stored and disposed of?

How to Store and Dispose of Forcilin?

Strict adherence to the official storage and disposal requirements ensures the drug's quality and safety. Official regulatory documents establish precise constraints covering temperature, environmental protection, and final disposal.


Official Storage Requirements

Requirement Official Regulatory Mandate
Temperature Control Store the product below the maximum stated temperature (e.g., 25°C or 30°C). Do not freeze or expose to excessive heat.
Protection & Handling Store in the original container to protect from light and moisture. Keep the container tightly closed.
Stability If applicable, any product unused after a defined in-use stability period (e.g., 24 hours after reconstitution) must be immediately discarded.
Child Safety Keep out of the sight and reach of children at all times.

Official Disposal Rules

Disposal instructions mandated by regulatory authorities require that unused or expired medicine be returned to a local drug take-back program or pharmacy collection point. Medicines must not be disposed of by flushing them down a toilet or pouring them into a drain to mitigate environmental risk. Sharps, if used, must be placed in an approved, puncture-proof sharps container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Forcilin found in:

A-Z Index: